Xinjing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinjing Chen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Yansong Guo
Department of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China
4 shared publicationsJingxuan Hong
Department of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China
3 shared publications- Mingcheng Fang
Department of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China
2 shared publications - Xianbao Liu
Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
2 shared publications - Beibei Du
The Institute of Cardiovascular Sciences, the Institute of Systems Biomedicine, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing, China
1 shared publication Fuchun Zhong
Department of Laboratory Medicine, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Maternity and Child Health Hospital, Fujian Medical University, Fuzhou, China
1 shared publication
Latest Publications
- Open Access
- 18 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (27) , 108304
A Combined Strategy for TAVR in High-Risk Anatomy
- 18 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (27) , 108304
Open AccessA Combined Strategy for TAVR in High-Risk Anatomy
- 10 March 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (5) , 1-23
Dexmedetomidine Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting DNMT3B-Mediated Hypermethylation of the KLF4 Promoter
- 10 March 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (5) , 1-23
Dexmedetomidine Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting DNMT3B-Mediated Hypermethylation of the KLF4 Promoter
- Open Access
- 29 October 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-18
Global trends and research hotspots in transcatheter valve replacement for aortic regurgitation: a bibliometric and visualized analysis
Transcatheter valve replacement (TAVR) has emerged as a pivotal intervention for aortic regurgitation(AR), garnering significant attention over the past two decades. Despite the proliferation of research in this domain, a comprehensive synthesis of the extant literature remains lacking, especially regarding large-scale randomized trials and long-term follow-up data. This study aims to elucidate the evolving landscape and current focal points of TAVR in the context of AR through advanced text mining and knowledge mapping techniques over the past 20 years and to project future development prospects. A systematic retrieval of medical literature regarding TAVR for AR was conducted within the Web of Science database’s Science Citation Index Expanded (SCIE), encompassing publications from 2004 to 2023. Analytical tools performed bibliometric and visualization analyses, including Microsoft Excel, CiteSpace, Bibliometrics, and VOSviewer. The analysis encompassed 2,189 publications across 200 journals, revealing a consistent upward publication volume and citation frequency trend. Notably, Leon, Martin B, Webb, John G, and Rodes-Cabau, Josep emerged as the most prolific scholars, while Catheterization and Cardiovascular Interventions ranked as the journal with the highest output. Geographically, the United States, Germany, and Italy led in publication output. The top 10 institutions with the most considerable influence were all from the European and American countries. A cluster analysis of the 169 keywords with a frequency exceeding 20 occurrences emphasized integrating procedural innovation, patient-specific risk assessment, and long-term outcome evaluation, highlighting the evolving priorities in advancing TAVR therapy for AR. Furthermore, operative techniques, valve device systems, and bioengineering technologies are likely to emerge as key research directions for the future treatment of AR with TAVR. This study is the first comprehensive bibliometric analysis of TAVR for AR, offering insights into health-oriented research trends. Despite advancements in clinical studies, minimally invasive surgical techniques, and bioengineering, prioritizing translational research to address patient health outcomes remains critical. Bridging innovation and clinical practice is vital to optimize therapeutic efficacy, improve quality of life, and reduce AR’s global health burden. Future research should integrate multidisciplinary approaches to enhance TAVR’s safety, accessibility, and long-term health benefits for diverse populations.
- 29 October 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-18
Open AccessGlobal trends and research hotspots in transcatheter valve replacement for aortic regurgitation: a bibliometric and visualized analysis
Transcatheter valve replacement (TAVR) has emerged as a pivotal intervention for aortic regurgitation(AR), garnering significant attention over the past two decades. Despite the proliferation of research in this domain, a comprehensive synthesis of the extant literature remains lacking, especially regarding large-scale randomized trials and long-term follow-up data. This study aims to elucidate the evolving landscape and current focal points of TAVR in the context of AR through advanced text mining and knowledge mapping techniques over the past 20 years and to project future development prospects. A systematic retrieval of medical literature regarding TAVR for AR was conducted within the Web of Science database’s Science Citation Index Expanded (SCIE), encompassing publications from 2004 to 2023. Analytical tools performed bibliometric and visualization analyses, including Microsoft Excel, CiteSpace, Bibliometrics, and VOSviewer. The analysis encompassed 2,189 publications across 200 journals, revealing a consistent upward publication volume and citation frequency trend. Notably, Leon, Martin B, Webb, John G, and Rodes-Cabau, Josep emerged as the most prolific scholars, while Catheterization and Cardiovascular Interventions ranked as the journal with the highest output. Geographically, the United States, Germany, and Italy led in publication output. The top 10 institutions with the most considerable influence were all from the European and American countries. A cluster analysis of the 169 keywords with a frequency exceeding 20 occurrences emphasized integrating procedural innovation, patient-specific risk assessment, and long-term outcome evaluation, highlighting the evolving priorities in advancing TAVR therapy for AR. Furthermore, operative techniques, valve device systems, and bioengineering technologies are likely to emerge as key research directions for the future treatment of AR with TAVR. This study is the first comprehensive bibliometric analysis of TAVR for AR, offering insights into health-oriented research trends. Despite advancements in clinical studies, minimally invasive surgical techniques, and bioengineering, prioritizing translational research to address patient health outcomes remains critical. Bridging innovation and clinical practice is vital to optimize therapeutic efficacy, improve quality of life, and reduce AR’s global health burden. Future research should integrate multidisciplinary approaches to enhance TAVR’s safety, accessibility, and long-term health benefits for diverse populations.
- Open Access
- 19 April 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (10) , 103939
Extreme Anchoring
- 19 April 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (10) , 103939
Open AccessExtreme Anchoring
- Open Access
- 29 May 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (22) , e20305
Intracoronary and peripheral blood levels of TNF-like Cytokine 1A (TL1A) in patients with acute coronary syndrome
Background: TNF-like cytokine 1A (TL1A) is a subgroup of the tumor necrosis factor superfamily that exerts pleiotropic effects on cell proliferation, inflammation, activation, and differentiation of immune cells. The purpose of the current study is to investigate the clinical significance of TL1A expression in coronary and peripheral blood of patients with acute coronary syndrome (ACS) to determine if TL1A levels can serve as an accurate prognostic indicator. Methods: A total of 141 patients undergoing coronary angiography were divided into 4 groups: Control (n = 35), Unstable Angina (UA) (n = 35), acute non-ST segment elevation myocardial infarction (NSTEMI) (n = 37), and acute ST segment elevation myocardial infarction (STEMI) (n = 34). The levels of TL1A, MPO, hs-CRP, and IL-10 were detected in coronary and peripheral blood using enzyme linked immunosorbent assay (ELISA), and the MACE incidence rates were compared during 26.3 months of follow-up. Results: TL1A levels were not significantly different between the UA group and control group. In the UA group, TL1A levels were not significantly different between coronary blood and peripheral blood. However, TL1A levels were higher in the STEMI and NSTEMI groups than in the control group (P < .05). Moreover, TL1A levels in the coronary blood of the STEMI and NSTEMI groups were higher than in the peripheral blood (P < .05). The expression of TL1A in the coronary blood was the highest in the STEMI group. In addition, TL1A level in the coronary blood was highly correlated with levels in the peripheral blood (correlation coefficient: 0.899, P < .001). The hs-CRP and MPO levels in the coronary and peripheral blood of all the UA, NSTEMI, and STEMI groups were higher than the control group. Plasma IL-10 levels in all the UA, NSTEMI and STEMI groups were lower than those in the control group. Plasma TL1A level was positively correlated with the cTnI level, degree of coronary thrombus burden, occurrence of slow coronary flow / no coronary reflow and MACE, but negatively correlated with the IL-10 level or non-correlated with the Syntax score. Conclusion: Plasma TL1A concentration levels can be used as a predictor of inflammatory response and prognosis in patients with ACS. Trial Registration: ClinicalTrials.gov, number: NCT02430025; Unique Protocol ID: FJPH20150101; Brief Title: Fujian Province Cardiovascular Diseases Study (FJCVD)
- 29 May 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (22) , e20305
Open AccessIntracoronary and peripheral blood levels of TNF-like Cytokine 1A (TL1A) in patients with acute coronary syndrome
Background: TNF-like cytokine 1A (TL1A) is a subgroup of the tumor necrosis factor superfamily that exerts pleiotropic effects on cell proliferation, inflammation, activation, and differentiation of immune cells. The purpose of the current study is to investigate the clinical significance of TL1A expression in coronary and peripheral blood of patients with acute coronary syndrome (ACS) to determine if TL1A levels can serve as an accurate prognostic indicator. Methods: A total of 141 patients undergoing coronary angiography were divided into 4 groups: Control (n = 35), Unstable Angina (UA) (n = 35), acute non-ST segment elevation myocardial infarction (NSTEMI) (n = 37), and acute ST segment elevation myocardial infarction (STEMI) (n = 34). The levels of TL1A, MPO, hs-CRP, and IL-10 were detected in coronary and peripheral blood using enzyme linked immunosorbent assay (ELISA), and the MACE incidence rates were compared during 26.3 months of follow-up. Results: TL1A levels were not significantly different between the UA group and control group. In the UA group, TL1A levels were not significantly different between coronary blood and peripheral blood. However, TL1A levels were higher in the STEMI and NSTEMI groups than in the control group (P < .05). Moreover, TL1A levels in the coronary blood of the STEMI and NSTEMI groups were higher than in the peripheral blood (P < .05). The expression of TL1A in the coronary blood was the highest in the STEMI group. In addition, TL1A level in the coronary blood was highly correlated with levels in the peripheral blood (correlation coefficient: 0.899, P < .001). The hs-CRP and MPO levels in the coronary and peripheral blood of all the UA, NSTEMI, and STEMI groups were higher than the control group. Plasma IL-10 levels in all the UA, NSTEMI and STEMI groups were lower than those in the control group. Plasma TL1A level was positively correlated with the cTnI level, degree of coronary thrombus burden, occurrence of slow coronary flow / no coronary reflow and MACE, but negatively correlated with the IL-10 level or non-correlated with the Syntax score. Conclusion: Plasma TL1A concentration levels can be used as a predictor of inflammatory response and prognosis in patients with ACS. Trial Registration: ClinicalTrials.gov, number: NCT02430025; Unique Protocol ID: FJPH20150101; Brief Title: Fujian Province Cardiovascular Diseases Study (FJCVD)